Nama's AI scorecard currently rates argenx Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ARGX's P/E ratio?

argenx trades at a trailing price-to-earnings ratio of 32.4.

When does ARGX report earnings?

argenx's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $7.32.

What is the ARGX price target?

The median analyst price target from 23 analysts is $1,130.00, with a range of $861.00 – $1,353.00.

Is ARGX Shariah compliant?

Nama's AAOIFI-style screen reads argenx as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

argenx (ARGX)

Healthcare · Biotechnology · NASDAQ

argenx (ARGX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $58.31B, a trailing price-to-earnings ratio of 32.4 and a free-cash-flow yield of 0.9%. Over the most recent reported fiscal year, revenue grew 89.6%. Nama's AI scorecard rates it Buy, 6.5 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 6.5/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Middle · +9.1% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-13.6%

How far the last close sits under the highest price of the past five years.

Market cap	$58.31B
Trailing P/E	32.4
Price / book	6.9
Price / sales	9.9
FCF yield	0.9%
Dividend yield	—
Gross margin	90.0%
Operating margin	29.8%
Net margin	32.2%
Revenue growth (YoY)	+89.6%
Revenue growth (3-yr annual)	+116.2%
EPS growth (YoY)	+1159.3%
FCF/share growth (YoY)	—
Beta	-0.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ARGX earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $7.32). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 22, 2026	$7.80	-$27.83	+128.0%	$1.72B
Q2 2026	Jul 23, 2026	$7.32	$6.19	+18.3%	$1.51B
Q1 2026	May 7, 2026	$5.52	$4.92	+12.2%	$1.30B
Q4 2025	Feb 26, 2026	$8.02	$6.11	+31.3%	$1.29B

ARGX analyst price target

Median target $1,130.00 from 23 analysts, ranging $861.00 – $1,353.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9
ROIV	Roivant Sciences	$28.08B	—

Explore live ARGX data on Nama Insights →

Recent Congressional trades

argenx trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Daniel Goldman	House	Sell	$1,001 - $15,000	Aug 13, 2023

ARGX FAQ

Is ARGX a buy?: Nama's AI scorecard currently rates argenx Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ARGX's P/E ratio?: argenx trades at a trailing price-to-earnings ratio of 32.4.
When does ARGX report earnings?: argenx's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $7.32.
What is the ARGX price target?: The median analyst price target from 23 analysts is $1,130.00, with a range of $861.00 – $1,353.00.
Is ARGX Shariah compliant?: Nama's AAOIFI-style screen reads argenx as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.